Aclaris Therapeutics

ACRS57

Penny Stock

$1.15arrow_drop_down4.95%-$0.06

Penny Stock

ACRS57

$1.15

arrow_drop_down4.95%-$0.06

Penny Stock

Performance History

Key Stats
Open	$1.22
Prev. Close	$1.21
EPS	-0.82
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$82.04M
PE Ratio	-

	LOW	HIGH
Day Range	1.15	1.22
52 Week Range	0.59	7.46

Ratios







EPS	-0.82

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Aclaris Therapeutics (ACRS)

Aclaris Therapeutics Inc (ACRS) is a biopharmaceutical company that focuses on developing and commercializing innovative treatments for dermatological conditions. The company's primary areas of focus include immunology, inflammation, and oncology. Aclaris Therapeutics Inc has a market cap of $xxx million, with a PEG ratio of xxx, which indicates that the stock may be undervalued. Aclaris Therapeutics Inc operates in the healthcare sector, which has a market cap of $xxx billion. The company has been performing well compared to its industry, with a stock price that has outperformed the industry average over the past year. Aclaris Therapeutics Inc's 52-week range is between $xx and $xx, and its day range is between $xx and $xx. The stock has a high trading volume, indicating strong investor interest.

Aclaris Therapeutics Inc has been making headlines in the news recently, with several exciting developments. The company recently announced positive results from a phase 3 clinical trial for its lead product candidate, which is being developed for the treatment of a common dermatological condition. This news has been well received by investors, and the stock price has experienced a significant increase as a result. Aclaris Therapeutics Inc is also actively pursuing collaborations and partnerships to further enhance its product portfolio and accelerate its growth. The company's smart analysis indicates that it has a solid financial position, with a positive cash flow and a healthy balance sheet. Aclaris Therapeutics Inc has a strong pipeline of product candidates and is well positioned for future success in the dermatology market.

Websitecall_made

Sector: Healthcare
Industry: Diagnostics & Research
CEO: Dr. Douglas J. Manion Frcp(C), M.D.
Headquarters: Wayne
Employees: 100
Exchange: NASDAQ

Keep an eye on Aclaris Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Aclaris Therapeutics 's (ACRS) price per share?

The current price per share for Aclaris Therapeutics (ACRS) is $1.15. The stock has seen a price change of -$0.06 recently, indicating a -4.96% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Aclaris Therapeutics (ACRS)?

For Aclaris Therapeutics (ACRS), the 52-week high is $7.46, which is 549.13% from the current price. The 52-week low is $0.59, the current price is 94.92% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Aclaris Therapeutics (ACRS) a growth stock?

Aclaris Therapeutics (ACRS) has shown an average price growth of 0.41% over the past three years. It has received a score of 3 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Aclaris Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Aclaris Therapeutics (ACRS) stock price performance year to date (YTD)?

As of the latest data, Aclaris Therapeutics (ACRS) has a year-to-date price change of 9.52%. Over the past month, the stock has experienced a price change of -8%. Over the last three months, the change has been 1.77%. Over the past six months, the figure is -3.36%. Looking at a longer horizon, the five-year price change stands at -19.01%.

help

Is Aclaris Therapeutics (ACRS) a profitable company?

Aclaris Therapeutics (ACRS) has a net income of -$88.48M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 42.14% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -457.48% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $31.25M, with a revenue growth rate of 5.03%, providing insight into the company's sales performance and growth. The gross profit is $13.17M. Operating income is noted at -$97.36M. Furthermore, the EBITDA is -$82.15M.

help

What is the market capitalization of Aclaris Therapeutics (ACRS)?

Aclaris Therapeutics (ACRS) has a market capitalization of $82.05M. The average daily trading volume is 261.87K, indicating the stock's liquidity and investor engagement.